DK2956443T3 - Hydantoiner som modulatorer af BACE-medieret APP-forarbejdning - Google Patents
Hydantoiner som modulatorer af BACE-medieret APP-forarbejdning Download PDFInfo
- Publication number
- DK2956443T3 DK2956443T3 DK14751458.2T DK14751458T DK2956443T3 DK 2956443 T3 DK2956443 T3 DK 2956443T3 DK 14751458 T DK14751458 T DK 14751458T DK 2956443 T3 DK2956443 T3 DK 2956443T3
- Authority
- DK
- Denmark
- Prior art keywords
- bace
- hydantoins
- modulators
- app processing
- mediated app
- Prior art date
Links
- 102100021257 Beta-secretase 1 Human genes 0.000 title 1
- 101000894895 Homo sapiens Beta-secretase 1 Proteins 0.000 title 1
- 150000001469 hydantoins Chemical class 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/70—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361763830P | 2013-02-12 | 2013-02-12 | |
| PCT/US2014/016100 WO2014127042A1 (en) | 2013-02-12 | 2014-02-12 | Hydantoins that modulate bace-mediated app processing |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2956443T3 true DK2956443T3 (da) | 2020-01-20 |
Family
ID=51354522
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14751458.2T DK2956443T3 (da) | 2013-02-12 | 2014-02-12 | Hydantoiner som modulatorer af BACE-medieret APP-forarbejdning |
Country Status (11)
| Country | Link |
|---|---|
| US (6) | US20140371283A1 (enExample) |
| EP (2) | EP3653609B1 (enExample) |
| JP (2) | JP6471100B2 (enExample) |
| KR (2) | KR102220259B1 (enExample) |
| CN (1) | CN104995176B (enExample) |
| AU (1) | AU2014216390B2 (enExample) |
| CA (1) | CA2899938C (enExample) |
| DK (1) | DK2956443T3 (enExample) |
| ES (2) | ES2975235T3 (enExample) |
| IL (1) | IL240555B (enExample) |
| WO (1) | WO2014127042A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2899938C (en) | 2013-02-12 | 2021-10-19 | Buck Institute For Research On Aging | Hydantoins that modulate bace-mediated app processing |
| AU2016220049C1 (en) | 2015-02-18 | 2021-02-25 | Buck Institute For Research On Aging | Triazolopyridines and triazolopyrimidines that lower stress-induced p-tau |
| KR20180090778A (ko) | 2015-08-27 | 2018-08-13 | 난트뉴로, 엘엘씨 | App-선택적 bace 억제를 위한 조성물 및 그의 용도 |
| WO2017096049A1 (en) | 2015-12-03 | 2017-06-08 | The University Of North Carolina At Pembroke | Materials for cathepsin b enhancement and methods of use |
| US10532102B2 (en) | 2016-08-19 | 2020-01-14 | Foresee Pharmaceuticals Co., Ltd. | Pharmaceutical composition and methods of uses |
| CA3034032C (en) * | 2016-08-19 | 2021-05-25 | Foresee Pharmaceuticals Co., Ltd. | Compositions comprising inhibitors of macrophage elastase and cyclodextrin |
| CN107353239B (zh) | 2017-08-11 | 2019-06-18 | 北京卓凯生物技术有限公司 | 4-氧-烷基化特特拉姆酸类化合物及其制备方法 |
| CN107468690B (zh) | 2017-08-11 | 2020-01-31 | 北京卓凯生物技术有限公司 | 4-氧-烷基化特特拉姆酸类化合物及其制备方法与应用 |
| US20210101879A1 (en) * | 2018-03-01 | 2021-04-08 | The Regents Of The University Of California | AMYLOID PROTEIN-SELECTIVE BACE INHIBITORS (ASBIs) FOR ALZHEIMER?S DISEASE |
| CN110652516A (zh) * | 2018-06-29 | 2020-01-07 | 上海绿谷制药有限公司 | 甘露糖醛二酸的组合物在治疗帕金森氏症中的应用 |
| US12208027B2 (en) | 2018-12-04 | 2025-01-28 | The Brain Protection Company PTY LTD | Combinatorial therapies including implantable damping devices and therapeutic agents for treating a condition and associated systems and methods of use |
| EP3890618A4 (en) * | 2018-12-04 | 2023-01-11 | The Brain Protection Company PTY Ltd | COMBINATIONAL THERAPIES COMPRISING IMPLANTABLE DAMPING DEVICES AND THERAPEUTIC AGENTS FOR TREATING A CONDITION AND SYSTEMS AND METHODS OF USE THEREOF |
| US11926599B1 (en) | 2023-10-23 | 2024-03-12 | King Faisal University | 1-(2-chlorobenzylideneamino)-5,5-diphenylimidazolidine-2,4-dione as an antimicrobial compound |
Family Cites Families (103)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4995971A (enExample) * | 1973-01-27 | 1974-09-11 | ||
| DE2448869A1 (de) | 1973-10-19 | 1975-09-04 | Mcneilab Inc | 4-oxo-2-imidazolidinylidenharnstoffe, verfahren zu ihrer herstellung und arzneimittel |
| US4025517A (en) * | 1975-06-23 | 1977-05-24 | Mcneil Laboratories, Incorporated | 4-Oxo-2-hexahydropyrimidinylidene ureas |
| JPS554305A (en) | 1978-06-13 | 1980-01-12 | Nippon Zoki Pharmaceut Co Ltd | Remedy for disease caused by stress and its preparation |
| US5070100A (en) | 1983-09-14 | 1991-12-03 | Alcon Laboratories, Inc. | Spiro-tricyclicaromatic succinimide derivatives |
| US4864028A (en) * | 1983-09-14 | 1989-09-05 | Alcon Laboratories, Inc. | Spiro-tricyclicaromatic succinimide derivatives |
| GB2189699A (en) | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated acid-labile medicaments |
| GB2189698A (en) | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
| CH677886A5 (enExample) | 1989-06-26 | 1991-07-15 | Hans Georg Prof Dr Weder | |
| ES2217250T3 (es) | 1990-06-15 | 2004-11-01 | Scios Inc. | Mamifero transgenico, no humano que muestra la patologia de formacion amiloides de la enfermedad de alzheimer. |
| WO1992013069A1 (en) | 1991-01-21 | 1992-08-06 | Imperial College Of Science, Technology & Medicine | Test and model for alzheimer's disease |
| DK0620849T3 (da) | 1992-01-07 | 2003-10-20 | Elan Pharm Inc | Transgene dyremodeller for Alzheimer's sygdom |
| US5604102A (en) | 1992-04-15 | 1997-02-18 | Athena Neurosciences, Inc. | Methods of screening for β-amyloid peptide production inhibitors |
| WO1995011968A1 (en) | 1993-10-27 | 1995-05-04 | Athena Neurosciences, Inc. | Transgenic animals harboring app allele having swedish mutation |
| US5877399A (en) | 1994-01-27 | 1999-03-02 | Johns Hopkins University | Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease |
| ES2094688B1 (es) | 1994-08-08 | 1997-08-01 | Cusi Lab | Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion. |
| FR2730932B1 (fr) | 1995-02-27 | 1997-04-04 | Oreal | Nanoemulsion transparente a base de lipides amphiphiles non-ioniques fluides et utilisation en cosmetique ou en dermopharmacie |
| JPH11507538A (ja) | 1995-06-07 | 1999-07-06 | アテナ ニューロサイエンシズ インコーポレイティド | β−セクレターゼ、β−セクレターゼに対する抗体、及びβ−セクレターゼ阻害を検出するためのアッセイ |
| US5744346A (en) | 1995-06-07 | 1998-04-28 | Athena Neurosciences, Inc. | β-secretase |
| FR2742676B1 (fr) | 1995-12-21 | 1998-02-06 | Oreal | Nanoemulsion transparente a base de tensioactifs silicones et utilisation en cosmetique ou en dermopharmacie |
| FR2755854B1 (fr) | 1996-11-15 | 1998-12-24 | Oreal | Nanoemulsion a base de lipides amphiphiles non-ioniques et cationiques et utilisations |
| FR2760970B1 (fr) | 1997-03-18 | 2000-03-10 | Oreal | Nanoemulsions a base de lipides amphiphiles non-ioniques et de silicones aminees et utilisations |
| AU5002399A (en) | 1998-07-17 | 2000-02-07 | National Broach And Machine Company | Full form roll finishing technique |
| NZ510708A (en) | 1998-09-24 | 2003-12-19 | Upjohn Co | Alzheimer's disease and Asp1 and Asp2 cleaving APP site (beta secretase) |
| FR2787026B1 (fr) | 1998-12-14 | 2001-01-12 | Oreal | Nanoemulsion a base d'esters mixtes d'acide gras ou d'alcool gras, d'acide carboxylique et de glyceryle, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique |
| FR2787027B1 (fr) | 1998-12-14 | 2001-01-12 | Oreal | Nanoemulsion a base d'esters gras de sucre ou d'ethers gras de sucre et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique |
| FR2787325B1 (fr) | 1998-12-17 | 2001-01-26 | Oreal | Nanoemulsion a base d'esters gras de sorbitan oxyethylenes ou non oxyethylenes, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique |
| FR2787326B1 (fr) | 1998-12-17 | 2001-01-26 | Oreal | Nanoemulsion a base d'esters gras de glycerol, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique |
| FR2787728B1 (fr) | 1998-12-23 | 2001-01-26 | Oreal | Nanoemulsion a base d'esters gras d'acide phosphorique, et ses utilisations dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique |
| FR2787703B1 (fr) | 1998-12-29 | 2001-01-26 | Oreal | Nanoemulsion a base d'ethers gras ethoxyles ou d'esters gras ethoxyles, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique |
| FR2788007B1 (fr) | 1999-01-05 | 2001-02-09 | Oreal | Nanoemulsion a base de copolymeres blocs d'oxyde d'ethylene et d'oxyde de propylene, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique |
| FR2788449B1 (fr) | 1999-01-14 | 2001-02-16 | Oreal | Nanoemulsion a base de citrates d'alkylether, et ses utilisations dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique |
| FR2789076B1 (fr) | 1999-02-02 | 2001-03-02 | Synthelabo | Derives de alpha-azacyclomethyl quinoleine, leur preparation et leur application en therapeutique |
| US7161962B1 (en) | 1999-05-27 | 2007-01-09 | Nuera Communications, Inc. | Method and apparatus for coding modem signals for transmission over voice networks |
| FR2811564B1 (fr) | 2000-07-13 | 2002-12-27 | Oreal | Nanoemulsion contenant des polymeres non ioniques, et ses utilisations notamment dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique |
| AU2002241823A1 (en) | 2001-01-11 | 2002-07-24 | Eastman Chemical Company | Cyclodextrin sulfonates, guest inclusion complexes, methods of making the same and related materials |
| FR2819427B1 (fr) | 2001-01-18 | 2003-04-11 | Oreal | Nanoemulsion translucide, son procede de fabrication et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique |
| EP2545937A1 (en) | 2001-06-05 | 2013-01-16 | The Regents Of The University Of Michigan | Nanoemulsion vaccines |
| US7476393B2 (en) | 2002-11-29 | 2009-01-13 | L'oreal | Process for the preparation of a cationic nanoemulsion, and cosmetic composition |
| ATE424383T1 (de) | 2003-08-08 | 2009-03-15 | Schering Corp | Cyclische amine mit benzamidsubstituent als bace- 1-inhibitoren |
| US7598250B2 (en) | 2003-08-08 | 2009-10-06 | Schering Corporation | Cyclic amine BACE-1 inhibitors having a heterocyclic substituent |
| US7592348B2 (en) | 2003-12-15 | 2009-09-22 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| SG163508A1 (en) | 2003-12-15 | 2010-08-30 | Schering Corp | Heterocyclic aspartyl protease inhibitors |
| US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| US7468402B2 (en) | 2004-03-17 | 2008-12-23 | Baker Hughes Incorporated | Polymeric nanoemulsion as drag reducer for multiphase flow |
| CA2561532A1 (en) | 2004-04-02 | 2005-10-20 | Merck & Co., Inc. | Methods for detecting substances which bind to the amyloid precursor protein or beta amyloid fragments, and binding compounds |
| EP1740573A1 (en) | 2004-04-22 | 2007-01-10 | Eli Lilly And Company | Amides as bace inhibitors |
| IL162288A0 (en) | 2004-06-01 | 2005-11-20 | Future Products Man S A | Compositions and methods for treating neurodegenerative disorders |
| JP2008503460A (ja) | 2004-06-16 | 2008-02-07 | ワイス | β−セクレターゼのインヒビターとしてのジフェニルイミダゾピリミジンおよびイミダゾールアミン |
| ATE444962T1 (de) | 2004-06-16 | 2009-10-15 | Wyeth Corp | Amino-5,5-diphenylimidazolon-derivate zur beta- sekretase-hemmung |
| DE602005025363D1 (de) | 2004-07-22 | 2011-01-27 | Schering Corp | Substituierte amide als inhibitoren der beta-sekretase |
| ATE396990T1 (de) | 2004-07-28 | 2008-06-15 | Schering Corp | Makrocyclische inhibitoren der beta-sekretase |
| SV2006002232A (es) | 2004-09-21 | 2006-05-25 | Lilly Co Eli | Inhibidores bace ref. x-16940 |
| GB0500683D0 (en) | 2005-01-13 | 2005-02-23 | Novartis Ag | Organic compounds |
| BRPI0606636A2 (pt) | 2005-01-13 | 2009-07-07 | Novartis Ag | compostos macrocìclicos úteis como inibidores de bace |
| AU2006259574A1 (en) | 2005-06-14 | 2006-12-28 | Schering Corporation | The preparation and use of compounds as aspartyl protease inhibitors |
| EP1896406A2 (en) | 2005-06-14 | 2008-03-12 | Shering Corporation | The preparation and use of compounds as protease inhibitors |
| US7759353B2 (en) | 2005-06-14 | 2010-07-20 | Schering Corporation | Substituted spiro iminopyrimidinones as aspartyl protease inhibitors, compositions, and methods of treatment |
| CA2609562A1 (en) | 2005-06-14 | 2006-12-28 | Schering Corporation | Macrocyclic heterocyclic aspartyl protease inhibitors |
| SG162790A1 (en) | 2005-06-14 | 2010-07-29 | Schering Corp | Aspartyl protease inhibitors |
| ATE482214T1 (de) | 2005-06-14 | 2010-10-15 | Schering Corp | Aspartylproteasehemmer |
| EP1896032B1 (en) | 2005-06-14 | 2012-10-31 | Merck Sharp & Dohme Corp. | The preparation and use of compounds as protease inhibitors |
| TW200738683A (en) | 2005-06-30 | 2007-10-16 | Wyeth Corp | Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation |
| JP2009500329A (ja) | 2005-06-30 | 2009-01-08 | ワイス | アミノ−５−（６員）ヘテロアリールイミダゾロン化合物およびβ−セレクターゼ調節のためのその使用 |
| TW200730523A (en) | 2005-07-29 | 2007-08-16 | Wyeth Corp | Cycloalkyl amino-hydantoin compounds and use thereof for β-secretase modulation |
| AU2006294620A1 (en) | 2005-09-26 | 2007-04-05 | Wyeth | Amino-5- [4- (difluoromethoxy) phenyl] -5-phenylimidazolone compounds as inhibitors of the beta-secretase (bace) |
| ATE478070T1 (de) | 2005-10-27 | 2010-09-15 | Schering Corp | Heterozyklische aspartyl-proteasehemmer |
| EP1943246A1 (en) | 2005-10-31 | 2008-07-16 | Schering Corporation | Aspartyl protease inhibitors |
| CN101360716A (zh) | 2005-11-21 | 2009-02-04 | 阿斯利康(瑞典)有限公司 | 新颖的2-氨基-咪唑-4-酮化合物及其在制备用于治疗认知缺损、阿尔茨海默病、神经变性和痴呆的药物中的用途 |
| GB0602951D0 (en) | 2006-02-14 | 2006-03-29 | Novartis Ag | Organic Compounds |
| CN101460480A (zh) | 2006-04-05 | 2009-06-17 | 阿斯利康(瑞典)有限公司 | 2-氨基嘧啶-4-酮类化合物及其用于治疗或预防Aβ相关病理的用途 |
| GB0611064D0 (en) | 2006-06-05 | 2006-07-12 | Novartis Ag | Organic compounds |
| US8168641B2 (en) | 2006-06-12 | 2012-05-01 | Schering Corporation | Aspartyl protease inhibitors |
| TW200815447A (en) | 2006-06-14 | 2008-04-01 | Astrazeneca Ab | Novel compounds IV |
| TW200815449A (en) | 2006-06-14 | 2008-04-01 | Astrazeneca Ab | Novel compounds II |
| TW200815443A (en) | 2006-06-14 | 2008-04-01 | Astrazeneca Ab | Novel compounds I |
| TW200808796A (en) | 2006-06-14 | 2008-02-16 | Astrazeneca Ab | New compounds III |
| TW200815349A (en) | 2006-06-22 | 2008-04-01 | Astrazeneca Ab | New compounds |
| BRPI0715440A2 (pt) | 2006-07-20 | 2013-07-23 | Novartis Ag | compostos macrocÍclicos éteis como inibidores de bace |
| CA2656869A1 (en) | 2006-07-20 | 2008-01-24 | Novartis Ag | Macrocyclic lactams |
| MX2009005182A (es) | 2006-11-23 | 2009-05-25 | Novartis Ag | Derivados de 2-hidroxi-1,3-diamino-propano. |
| MX2009006228A (es) | 2006-12-12 | 2009-06-22 | Schering Corp | Inhibidores de aspartil proteasa. |
| CN101631779A (zh) | 2006-12-12 | 2010-01-20 | 先灵公司 | 含有三环系统的天冬氨酰蛋白酶抑制剂 |
| TW200831091A (en) * | 2006-12-20 | 2008-08-01 | Astrazeneca Ab | New compounds |
| CA2680307A1 (en) * | 2007-03-12 | 2008-09-18 | Merck & Co., Inc. | Monocyclic anilide spirolactam cgrp receptor antagonists |
| CL2008000784A1 (es) | 2007-03-20 | 2008-05-30 | Wyeth Corp | Compuestos amino-5-[-4-(diflourometoxi) fenil sustituido]-5-fenilmidazolona, inhibidores de b-secretasa; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar alzheimer, deterioro cognitivo, sindrome de down, disminucion co |
| TW200902499A (en) | 2007-05-15 | 2009-01-16 | Astrazeneca Ab | New compounds |
| US20090041201A1 (en) | 2007-08-06 | 2009-02-12 | Carestream Health, Inc. | Alignment apparatus for imaging system |
| CA2697254A1 (en) | 2007-08-23 | 2009-02-26 | Novartis Ag | Aminobenzyl-substituted cyclic sulfones useful as bace inhibitors |
| US20090062361A1 (en) | 2007-08-30 | 2009-03-05 | Allergan, Inc. | Therapeutic hydantoins |
| TWI431004B (zh) | 2008-05-02 | 2014-03-21 | Lilly Co Eli | Ｂａｃｅ抑制劑 |
| MX2011000390A (es) | 2008-07-10 | 2011-03-01 | Novartis Ag | Sulfonas ciclicas con sustitucion de amino-bencilo utiles coimo inhibidores de bace. |
| CN102186841A (zh) | 2008-10-22 | 2011-09-14 | 盐野义制药株式会社 | 具有bace1抑制活性的2-氨基嘧啶-4-酮及2-氨基吡啶衍生物 |
| WO2010054507A1 (zh) | 2008-11-11 | 2010-05-20 | 石药集团中奇制药技术（石家庄）有限公司 | 松属素环糊精或环糊精衍生物包合物 |
| AR077277A1 (es) | 2009-07-09 | 2011-08-17 | Lilly Co Eli | Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer |
| EP2485591B1 (en) | 2009-10-08 | 2016-03-23 | Merck Sharp & Dohme Corp. | Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| UA108363C2 (uk) | 2009-10-08 | 2015-04-27 | Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування | |
| CA2808630A1 (en) | 2010-08-19 | 2012-02-23 | Buck Institute For Age Research | Methods of treating mild cognitive impairment (mci) and related disorders |
| US8415483B2 (en) | 2010-12-22 | 2013-04-09 | Astrazeneca Ab | Compounds and their use as BACE inhibitors |
| US20120165346A1 (en) | 2010-12-22 | 2012-06-28 | Astrazeneca Ab | Compounds and their use as BACE inhibitors |
| US8877744B2 (en) | 2011-04-04 | 2014-11-04 | Hoffmann-La Roche Inc. | 1,4-Oxazepines as BACE1 and/or BACE2 inhibitors |
| CA2899938C (en) | 2013-02-12 | 2021-10-19 | Buck Institute For Research On Aging | Hydantoins that modulate bace-mediated app processing |
| KR20180090778A (ko) * | 2015-08-27 | 2018-08-13 | 난트뉴로, 엘엘씨 | App-선택적 bace 억제를 위한 조성물 및 그의 용도 |
-
2014
- 2014-02-12 CA CA2899938A patent/CA2899938C/en active Active
- 2014-02-12 JP JP2015557226A patent/JP6471100B2/ja active Active
- 2014-02-12 US US14/179,310 patent/US20140371283A1/en not_active Abandoned
- 2014-02-12 KR KR1020197035067A patent/KR102220259B1/ko active Active
- 2014-02-12 KR KR1020157021979A patent/KR102051485B1/ko active Active
- 2014-02-12 WO PCT/US2014/016100 patent/WO2014127042A1/en not_active Ceased
- 2014-02-12 ES ES19199279T patent/ES2975235T3/es active Active
- 2014-02-12 CN CN201480007825.4A patent/CN104995176B/zh active Active
- 2014-02-12 EP EP19199279.1A patent/EP3653609B1/en active Active
- 2014-02-12 AU AU2014216390A patent/AU2014216390B2/en active Active
- 2014-02-12 EP EP14751458.2A patent/EP2956443B1/en active Active
- 2014-02-12 US US14/764,107 patent/US10202355B2/en active Active
- 2014-02-12 ES ES14751458T patent/ES2769578T3/es active Active
- 2014-02-12 DK DK14751458.2T patent/DK2956443T3/da active
-
2015
- 2015-08-12 IL IL240555A patent/IL240555B/en active IP Right Grant
- 2015-10-30 US US14/928,775 patent/US9926280B2/en active Active
-
2017
- 2017-12-06 US US15/833,862 patent/US10766867B2/en active Active
-
2019
- 2019-01-17 JP JP2019005905A patent/JP6773820B2/ja active Active
- 2019-02-08 US US16/271,681 patent/US20200017449A1/en not_active Abandoned
-
2020
- 2020-01-10 US US16/740,110 patent/US11091444B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2956443T3 (da) | Hydantoiner som modulatorer af BACE-medieret APP-forarbejdning | |
| DK2968208T3 (da) | Behandling af kataplexi | |
| DK3087183T3 (da) | Modulation af angiopoietin-3-lignende ekspression | |
| DK3394033T3 (da) | Heterocykliske forbindelser som immunmodulatorer | |
| DK3331876T3 (da) | Modulators of ror-gamma | |
| DK3239134T3 (da) | Pyridonamider som modulatorer af natriumkanaler | |
| DK3080100T3 (da) | Hæmmere af lysinspecifik demethylase-1 | |
| EP2979402A4 (en) | FORWARDING OF PACKAGES | |
| DK2845905T3 (da) | Fremstilling af oligosaccharider | |
| HUE042443T2 (hu) | GPR6 tetrahidropiridopirazin-modulátorai | |
| DK2906696T4 (da) | Fremgangsmåder til modulering af c9orf72-ekspression | |
| DK2961388T3 (da) | Kombinationer af lægemidler | |
| DK2981255T3 (da) | Terapeutiske anvendelser af empagliflozin | |
| EP2877458A4 (en) | CYSTATHIONINE-Y-GAMMA-LYASE (CSE) -HEMMER | |
| EP2951148A4 (en) | S1P MODULATING MEDIUM | |
| DK3294713T5 (da) | Substituerede tetrahydroquinolinonforbindelser som ror-gamma-modulatorer | |
| PT2953948T (pt) | Antagonistas de integrina fluorada | |
| DK2970442T3 (da) | Gla-domæner som terapeutiske midler | |
| LT3038654T (lt) | Naujas panaudojimas | |
| DK2965026T3 (da) | Generering af slushice | |
| PT3071638T (pt) | Composição de cianoacrilato | |
| EP2988708A4 (en) | ANKLE SUPPORT | |
| DK3060226T3 (da) | Fagterapi af pseudomonasinfektioner | |
| DK3063264T3 (da) | Tørring af mikroorganismer | |
| EP2968296A4 (en) | GAMMASEKRETASEMODULATOREN |